NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has priced its Gattex drug for short bowel syndrome, or SBS, at $295,000, expecting to make peak sales of $350...
Keep Reading →
September 11 - News - Comments
We discussed Michael Castor’s Sio Capital earlier this summer, and in case you need convincing of why we called him “the next David Einhorn...
Keep Reading →
September 5 - Hedge Funds - Comments
If you were to ask many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age. Although there are more than...
Keep Reading →
September 4 - News - Comments
What’s a smart Puma Biotechnology Inc (NYSE:PBYI) investor to do? In today’s marketplace, there are dozens of methods market participants can...
Keep Reading →
September 3 - News - Comments
Is Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) a good investment? To the average investor, there are dozens of indicators market participants can use...
Keep Reading →
August 30 - News - Comments
In today’s marketplace, there are tons of gauges market participants can use to track their holdings. A duo of the most innovative are hedge fund and...
Keep Reading →
August 28 - News - Comments
MannKind Corporation (NASDAQ:MNKD) has gotten one of the biggest votes of confidence we’ve seen from the smart money, out of the entire stock market...
Keep Reading →
August 22 - News - Comments
There are few times when your doctor or physician will utter the phrase, “I don’t know” to a patient, but when you’re dealing...
Keep Reading →
August 5 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don’t have to imagine...
Keep Reading →
July 5 - News - Comments
Is Puma Biotechnology Inc (NYSE:PBYI) a buy here? Hedge funds are betting on the stock. The number of bullish hedge fund bets improved by 2 lately. In...
Keep Reading →
June 10 - News - Comments
“Making every patient count” is a catchy phrase that is perhaps most meaningful for biotech companies like NPS Pharmaceuticals, Inc. (NASDAQ...
Keep Reading →
June 4 - News - Comments
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) investors should pay attention to an increase in hedge fund interest in recent months. To most stock holders...
Keep Reading →
June 3 - News - Comments
Investments in biotechnology by the average investor tend to deliver hit or miss returns over time. Since inception, the SPDR S&P Biotech ETF has...
Keep Reading →
May 8 - News - Comments
What goes up must come down. Or can it just keep going up? Two high-flying biotech stocks of late are NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron...
Keep Reading →
April 16 - News - Comments
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has seen a decrease in enthusiasm from smart money in recent months. According to most investors, hedge funds...
Keep Reading →
April 8 - News - Comments
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is bringing its kids home. The biotech announced yesterday that it had reacquired the ex-North America rights...
Keep Reading →
March 22 - News - Comments
The hits keep coming at AstraZeneca plc (ADR) (NYSE:AZN). The struggling big pharma player has seen its stock taken down more than 6% so far in 2013,...
Keep Reading →
February 25 - News - Comments
Orphan drugs — medications meant for small patient populations with rare, dangerous diseases — can be a rewarding business for biotech firms...
Keep Reading →
February 22 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on...
Keep Reading →
February 20 - News - Comments
Stocks are rolling along unchallenged, surging to highs not seen since 2007. Investors are partying like it’s before the recession, but with many...
Keep Reading →
February 13 - News - Comments
A quick way to discover potentially undervalued stocks is to look for ones with a current price below the current mean analyst target price. Last year...
Keep Reading →
November 16 - Stock Analysis - Comments
